Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.28
- Piotroski Score 5.00
- Grade Buy
- Symbol (CDNA)
- Company CareDx, Inc
- Price $29.71
- Changes Percentage (-0.34%)
- Change -$0.1
- Day Low $29.50
- Day High $30.32
- Year High $34.84
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $34.50
- High Stock Price Target $40.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.42
- Trailing P/E Ratio -4.45
- Forward P/E Ratio -4.45
- P/E Growth -4.45
- Net Income $-190,284,000
Income Statement
Quarterly
Annual
Latest News of CDNA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CareDx, Inc (CDNA): Among the Best Organ Transplant and Diagnosis Stocks to Buy According to Hedge Funds?
The article discusses the importance and growth of the organ transplant and diagnosis industry, highlighting CareDx, Inc (NASDAQ:CDNA) as one of the top stocks to consider. The market is expanding due...
By Yahoo! Finance | 1 month ago -
Analysts Just Made A Substantial Upgrade To Their CareDx, Inc (NASDAQ:CDNA) Forecasts
Analysts have upgraded CareDx, Inc's revenue and earnings forecasts, leading to a 22% rise in the stock price. Revenue is expected to grow by 9.5% in 2024, with reduced losses....
By Yahoo! Finance | 1 month ago -
Earnings Beat: CareDx, Inc (NASDAQ:CDNA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
CareDx, Inc (NASDAQ:CDNA) reported strong second-quarter results, exceeding revenue forecasts by 36% with smaller losses than expected. Analysts predict revenue growth and decreased losses in 2024, le...
By Yahoo! Finance | 1 month ago
